Skip to main content
. Author manuscript; available in PMC: 2014 Oct 22.
Published in final edited form as: Psoriasis Forum. 2010 Summer;16(2):36–42.

Figure 2.

Figure 2

Median percentage improvement in Psoriasis Area and Severity Index (PASI) score from baseline at weeks 40 to 76 for ustekinumab (45 and 90 mg)

(Adapted with permission from Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial [PHOENIX 1]. Lancet. 2008;371:1665–74.)